SKINCARE
PDRN VS PN: WHAT AESTHETIC PRACTITIONERS NEED TO KNOW
As PDRN moves into topical skincare and injectable polynucleotides gain prominence in clinics, confusion surrounding the two categories is growing. Ellen Cummings examines their proposed mechanisms, evidence and implications for clinical practice.
Polynucleotides (PN) have become one of the most discussed categories in regenerative aesthetics, while polydeoxyribonucleotide (PDRN) is appearing in increasing numbers of creams, serums and professional skincare protocols.
Both are frequently associated with skin repair and regeneration, and the terms are sometimes used interchangeably. Yet differences in fragment length, molecular weight, formulation, route of administration and regulatory status mean evidence from one product or category cannot automatically be transferred to another. Understanding those distinctions is increasingly important for clinicians combining injectable treatments with professional skincare or advising patients about the topical products marketed around them.
FROM INJECTABLE TREATMENTS TO TOPICAL SKINCARE
PDRN’s growing profile can be traced to South Korea, where regenerative treatments have become part of a wider emphasis on skin quality, prevention and regular maintenance.
“PDRN first gained traction in Korea through the medical aesthetics and dermatology clinic space in the mid-2010s, particularly via injectable skin-booster treatments,” explains Poppy Smith from Pureseoul, a UK-based specialist retailer of Korean skincare. As these treatments became more widely recognised, Korean manufacturers began incorporating PDRN into creams, masks and serums.
“Consumers are becoming increasingly interested in skin longevity, barrier health and low-irritation skincare,” says Smith. “At the same time, the crossover between aesthetics and retail beauty has grown, with more consumers seeking clinic-inspired ingredients for at-home use.”
However, the movement of an ingredient from medical treatments into cosmetics does not mean the different products work in the same way. The route of administration, molecular characteristics and formulation all influence what an ingredient can plausibly achieve.
DEFINING PN AND PDRN
Both PN and PDRN comprise DNA-derived fragments, traditionally obtained from salmon or trout reproductive material. However, terminology and molecular specifications are not applied consistently across the international market.
Within PharmaResearch’s own portfolio, injectable Rejuran contains longer, higher-molecular-weight PN, while its topical cosmetics use shorter PDRN fragments.
“PDRN is a shorter fragment, and this is what is in the cosmeceuticals,” explains Dr Michael Kim, chief medical officer and executive managing director of medical strategy at PharmaResearch. “It needs to be shorter for better absorption.”
The company says its proprietary DNA Optimizing Technology controls sourcing, fragment range, consistency and purification according to the intended product. Hongyeol Jeon, PharmaResearch’s vice-president and head of development, says its injectable PN and cosmetic PDRN occupy distinct molecular-weight ranges.
These descriptions relate specifically to PharmaResearch’s own materials. Practitioners should not assume every product labelled PN or PDRN has equivalent molecular characteristics, purity, concentration or biological behaviour.
“PN” and “PDRN” should therefore be treated as starting points for product evaluation, rather than evidence that different products are interchangeable.
DIFFERENT ROUTES REQUIRE DIFFERENT EVIDENCE
PDRN has been investigated in medical contexts including wound healing. A 2014 randomised, placebo-controlled study published in the Journal of Clinical Endocrinology & Metabolism assessed PDRN in 216 patients with difficult-to-heal diabetic foot ulcers. Complete healing at eight weeks was reported in 37.3% of the PDRN group and 18.9% of the placebo group.¹
However, PDRN was delivered through intramuscular and local injections. The findings cannot be used as evidence that an ordinary topical cosmetic will produce the same effect.
Similarly, evidence concerning one injectable PN product cannot establish the performance of another PN injectable with different molecular specifications.
Source, fragment distribution, concentration, excipients, purification and route of administration all matter. A study must be assessed in relation to the precise product, protocol and indication being offered.
PROPOSED MECHANISMS AND REMAINING QUESTIONS
PDRN has been associated with activation of the adenosine A2A receptor, regulation of inflammatory responses and support of the nucleotide salvage pathway, through which cells reuse components needed to produce DNA.
For its longer-chain injectable PN, PharmaResearch is investigating a proposed mechanism involving the formation of a temporary three-dimensional scaffold within tissue.
During the PharmaResearch Global Symposium in October 2026, Kim presented imaging that the company says demonstrates structural differences between its shorter PDRN fragments and longer PN chains. He hypothesised that the longer material may provide a structure to which fibroblasts can attach, potentially supporting their mechanical activity.
Kim was clear that this remains an area of investigation: “This is our hypothesis. This is what we want to research.”
That distinction is important. Structural imaging and laboratory models can support a proposed mechanism, but they do not in themselves establish a clinical outcome.
CAN TOPICAL PDRN PENETRATE THE SKIN?
Topical PDRN faces the same fundamental challenge as other relatively large, charged molecules: penetration through the stratum corneum.
“Traditionally, PDRN has been associated with injectable treatments, so naturally there are questions around how well it can perform when applied topically,” says Amy Holland-Rathmill, head of sales at Million Dollar Facial. “This is where the formulation and delivery method become important.”
Manufacturers are investigating shorter fragments, altered molecular structures and delivery technologies intended to improve absorption.
Simone Shoffman, education and clinical director at Healthxchange, describes one approach involving DNA chains folded into a three-dimensional tetrahedral structure. This is intended to address some of the limitations associated with conventional PDRN, although a theoretical delivery mechanism still requires relevant clinical evidence.
A 2026 study published in PLOS One examined a medium-length PDRN preparation through laboratory and skin models and a 28-day randomised, double-blind, split-face trial comparing a PDRN eye cream with retinol.²
The results suggested improvements in periocular wrinkles and certain skin measurements, alongside evidence of PDRN-associated material reaching viable epidermal layers.
However, the study concerned a specific preparation. It cannot show that all PDRN cosmetics penetrate or produce the same outcomes.
Similarly, a 2023 study in Molecules investigated ginseng-derived PDRN and reported activity in keratinocytes and fibroblasts and changes in barrier-related markers.³ These laboratory and reconstructed-skin findings should not be presented as proof of equivalent clinical results in patients.
FROM SKINCARE PRODUCT TO PROFESSIONAL PROTOCOL
Professional brands are increasingly incorporating PDRN into protocols involving microneedling, energy-based devices and recovery-focused treatments.
Depending on the formulation and manufacturer-approved protocol, PDRN may be applied as part of a facial, used after certain procedures or combined with delivery technologies.
Lauren Evans, training and development officer at CACI, explains that its needle-free approach uses ultrasonic atomisation, electro-infusion and LED alongside a plant-derived PDRN formulation. Other systems position PDRN concentrates alongside microneedling or as a post-procedure step.
This creates both opportunity and risk. A cosmetic formulation intended for intact skin is not automatically appropriate for application to compromised skin or delivery through microneedling-created channels.
Products used in this way should be assessed for sterility, excipients, packaging, device compatibility and manufacturer-authorised use.
Practitioners should also avoid attributing every improvement from a combined protocol to PDRN. Microneedling, radiofrequency, laser, LED and other modalities have established biological effects of their own. Without controlled comparative research, the contribution of an added product cannot be isolated.
The same principle applies to aftercare. A product marketed as soothing or regenerative may still contain preservatives, fragrance, solvents or other ingredients unsuitable for immediate post-procedure use.
SUPPORTING RESULTS THROUGH HOMECARE
Topical PDRN may have a more straightforward role within longer-term homecare than in protocols involving compromised skin.
“I would position PDRN as part of a wider skin-health routine rather than as a single miracle ingredient,” says Holland-Rathmill. “Good cleansing, hydration, barrier support and daily broad-spectrum sunscreen should always form the foundation of homecare.”
For patients undergoing professional or medical treatments, a suitable PDRN product may complement established barrier-support ingredients such as ceramides, panthenol and hyaluronic acid.
Nevertheless, evidence should relate to the specific formulation. The reputation of injectable polynucleotides or medical PDRN cannot substantiate the claims of every cosmetic containing the ingredient.
INJECTABLE TREATMENT PLANNING
For injectable Rejuran, Kim describes three to four sessions at intervals of approximately two to four weeks as a commonly studied protocol.
However, he emphasises that treatment should be individualised according to skin condition, sensitivity, recovery and response. Some patients may require longer intervals or additional sessions.
This protocol should not be generalised to every injectable PN product. Practitioners must check the product’s regulatory status and follow the applicable instructions for use in their market, supported by appropriate training and product-specific evidence. Combination treatment is another growing area. Kim predicts that clinics will increasingly combine modalities within the same appointment rather than treating them as isolated interventions.
That makes evidence-based sequencing increasingly important. The absence of an obvious interaction does not establish that simultaneous treatment is superior, and clinicians should distinguish published protocols from expert preference or commercial convenience.
SAFETY, SUITABILITY AND SOURCING
Fish-derived materials raise questions about purity, residual proteins, immunogenicity, allergies and patient preferences.
PharmaResearch says its manufacturing process controls fragment size and removes proteins and other contaminants. Practitioners should request the relevant product documentation rather than relying solely on category-wide or marketing claims.
They should establish:
• The biological source of the material
• Its molecular-weight or fragment distribution
• Purification and sterility standards
• Product-specific contraindications
• Allergy considerations
• Storage and traceability requirements
• Regulatory status and intended use
• Evidence supporting the proposed indication and technique
Plant-derived DNA fragments are also emerging in skincare, but they should not automatically be considered chemically or clinically equivalent to salmon-derived PDRN.
Suitability also depends on the complete formulation, rather than the presence of a headline ingredient alone.
A CATEGORY REQUIRING PRECISION
PN and PDRN may occupy related territory, but they should not be collapsed into a single interchangeable category.
The route of administration, molecular characteristics, formulation and intended use all influence what a product can plausibly achieve and which evidence is relevant.
For aesthetic practitioners, precision in terminology is more than an academic concern. It affects consent, treatment planning, product selection, claims, aftercare and patient expectations.
As interest in regenerative aesthetics continues to grow, the strongest clinics will be those able to separate a promising mechanism from a demonstrated outcome – and product-specific evidence from category-wide hype.
Disclosure: The author attended a press trip to South Korea hosted by PharmaResearch, during which travel, accommodation and activities were provided. No payment was received for this article, and editorial content remained independent.